~~<i id='9DDA365E75'><strike id='9DDA365E75'><tt id='9DDA365E75'><pre id='9DDA365E75'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：hotspot 2025-09-30 21:31:02 Page View：511

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Companies helping big Covid
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

explore

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

New research sheds light on how often breast cancer is overdiagnosed

Apatientundergoingamammogram.Newresearchsuggests1of7breastcancercasesdetectedduringscreeningsarewhat

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Inflation cooled significantly in June, bringing price hikes close to normal levels

1:39ProducepricesaredisplayedatagrocerystoreinBrooklyn,Feb.14,2023.XinhuaNewsAgencyviaGettyImagesCon